United States Brachial Plexus Injury Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

United States Brachial Plexus Injury Market Trends and Insights

Rising Traumatic Injury Burden From Road Accidents and Sports Incidents

Motorcycle accidents represented 32.8% of brachial plexus injury cases in trauma populations, and motor vehicle collisions accounted for another 16.7% of peripheral nerve injuries more broadly, which keeps a steady inflow of severe cases into the United States brachial plexus injury market.^{[1]Canadian Journal of Anesthesia, “Epidemiology of Peripheral Nerve and Brachial Plexus Injuries in a Trauma Population,” Canadian Journal of Anesthesia, pubmed.ncbi.nlm.nih.gov} This pattern matters because road trauma produces high-force cervical root damage that is more likely to need advanced imaging, surgical triage, and long rehabilitation than lower-energy nerve injuries. The sports burden also matters, especially in younger patients, because pediatric traumatic brachial plexus injury data showed that motor vehicle accidents accounted for 35% of cases and sports incidents for 28%. Those same data showed that microsurgery was indicated in 41% of traumatic cases compared with 13% of birth injury cases, which means trauma cases generate a higher surgical conversion rate once they enter specialist care. As a result, the United States brachial plexus injury market continues to depend on trauma volume not just for patient counts, but for a disproportionate share of complex and high-value treatment episodes.

High Surgical Receptivity for Severe Root Avulsion and Complex Plexus Damage

The United States brachial plexus injury market remains highly responsive to severe cases because root avulsion and complete brachial plexus disruptions carried a 53% operative management rate, and nerve transfers were used in 48% of all brachial plexus injury surgeries. Avulsion injuries create strong procedure demand because preganglionic root loss prevents standard graft-based repair and pushes surgeons toward extraplexal donor strategies such as intercostal transfer or contralateral C7 transfer.^{[2]Handchirurgie Mikrochirurgie Plastische Chirurgie, “Der Kontralaterale C7 Transfer,” Handchirurgie Mikrochirurgie Plastische Chirurgie, thieme-connect.com} Published clinical evidence in 2024 showed that contralateral C7 transfer is now viewed as a reliable pathway for patients with multiple root avulsions who lack intraplexal donor options, which expands the treatable population within the United States brachial plexus injury market. A 2025 meta-analysis also showed that upper trunk repairs achieved a 75% success rate, while complete injuries reached 29%, which reinforces the value of early case selection and rapid referral into specialized centers. That mix of technical feasibility and better-defined outcome expectations keeps surgery at the center of the United States brachial plexus injury market for the most disabling forms of nerve damage.

Faster Adoption of AI-Assisted Imaging and Intraoperative Nerve Monitoring

The United States brachial plexus injury market is seeing better diagnostic throughput as artificial intelligence compressed sensing for brachial plexus MRI reduced scan time by 55.1% at a 6.2x acceleration factor while preserving diagnostic image quality.^{[3]BMC Medical Imaging, “Comparison of Different Acceleration Factors of Artificial Intelligence Compressed Sensing for Brachial Plexus MRI Imaging Scanning Time and Image Quality,” BMC Medical Imaging, bmcmedimaging.biomedcentral.com} That change brings neurography below the old workflow barrier of lengthy scan slots and makes advanced imaging easier to use in busy trauma settings. Ultrasound guidance is improving as well, because a convolutional neural network model validated for brachial plexus segmentation at the interscalene level achieved a mean Dice coefficient of 0.748 and outperformed earlier deep learning benchmarks. Faster and more consistent imaging matters for the United States brachial plexus injury market because delayed recognition often pushes patients outside the surgical timing window before they reach a referral center. Better imaging at community and tertiary sites therefore supports a larger downstream procedure pool, not only a better diagnostic experience.

Higher Coverage for Medically Necessary Reconstructive Care and Rehabilitation

Coverage support is improving the procedure economics of the United States brachial plexus injury market because complex brachial plexus surgeries are generally recognized by Medicare and private insurers as medically necessary reconstructive care. The ambulatory setting has become more attractive since Pacira BioSciences received CMS proposed separate reimbursement support for EXPAREL in both ambulatory surgical centers and hospital outpatient departments, effective January 1, 2025, which lowers pain-management cost pressure around outpatient nerve procedures. CMS also created a new Level 3 Nerve Procedure Code for 2026, which gives nerve allograft repair a more visible reimbursement framework in outpatient care and supports continued site-of-care migration. At the same time, local coverage determinations for peripheral nerve blocks are still evolving, and providers need tighter documentation when therapeutic pathways overlap with chronic pain management. Even so, broader recognition of reconstructive need and rehabilitation value gives the United States brachial plexus injury market a firmer reimbursement base than it had a few years ago.

Narrow Surgical Timing Window Reduces Treatable Patient Pool

The United States brachial plexus injury market faces a hard biological limit because nerve regeneration moves at 1 mm per day, and delays beyond 3 to 6 months lower the chance of meaningful motor recovery. Early intervention matters in practical terms, since one multicenter series reported mean shoulder abduction of 110° for surgery performed within 6 months compared with 51° for delayed cases. This timing problem is especially important in the United States brachial plexus injury market because many patients first present to emergency departments or community hospitals that do not have a direct referral pathway into subspecialty nerve reconstruction. The result is not a full loss of demand, because those patients still use physical therapy and pain management, but it does remove them from the highest-value surgical funnel. That compression of eligible case volume limits how much revenue growth the United States brachial plexus injury market can realize from procedure innovation alone.

Scarcity of Subspecialty Surgeons Slows Referral-to-Treatment Conversion

The United States brachial plexus injury market also remains constrained by the limited number of surgeons with concentrated experience in complex plexus reconstruction. That shortage is visible in the way expertise clusters around a small group of academic and referral hubs, rather than across broad community-based orthopedic networks. The practical result is that patients in non-metropolitan regions often face longer referral times, more fragmented evaluation, and a greater chance of missing the preferred surgical window. This problem is harder to solve than a reimbursement gap because advanced brachial plexus reconstruction requires technical training, operating room support, and multidisciplinary follow-up that are not easily replicated outside specialized centers. Until that provider base widens, the United States brachial plexus injury market will continue to grow more slowly than the underlying burden of treatable cases would suggest.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type of Injury: Avulsion Dominance Persists as Neuroma Demand Rises

Avulsion held 34.48% of the United States brachial plexus injury market share in 2025, which reflects its close link with the high-energy trauma patterns that dominate severe adult presentations. Avulsion is the most procedurally demanding form of brachial plexus injury because the nerve root is torn from the spinal cord, which removes the option of standard intraplexal grafting in many cases. That clinical severity raises the average treatment intensity in the United States brachial plexus injury industry, because surgeons often need extraplexal donor strategies such as intercostal or spinal accessory transfers. It also increases the role of academic referral centers, since complete and near-complete plexus injuries demand higher operating room coordination, advanced imaging, and longer follow-up.

Neuroma is the fastest-growing injury subtype, with a 7.36% CAGR through 2031, as clinicians are paying closer attention to painful nerve sequelae after incomplete recovery or failed reconstruction. That shift broadens the United States brachial plexus injury market beyond acute trauma repair and pushes more attention toward chronic functional loss, pain relief, and revision pathways. Rupture and stretch injuries remain important because they create a stable base of lower-acuity treatment demand across diagnostics, medication, therapy, and rehabilitation. Together, that mix leaves the United States brachial plexus injury market anchored by avulsion in value terms, while neuroma expands the addressable pool in later-stage care.

By Treatment Type: Surgical Primacy Intact but Rehabilitation Gains Clinical Ground

Surgical treatment accounted for 51.17% of the United States brachial plexus injury market size in 2025, which confirms that procedure-based care still drives the largest share of revenue. That segment includes nerve repair, grafting, transfer, and microsurgical reconstruction, which together carry the highest procedural complexity and the strongest reimbursement intensity in the United States brachial plexus injury market. Nerve transfer was used in 48% of all brachial plexus injury surgeries, which shows how central reconstructive strategy has become in current practice. Published outcomes also favor more advanced transfer protocols in selected cases, with the Oberlin 2 technique showing stronger sEMG signals for elbow flexion recovery than intercostal-to-musculocutaneous transfers.

Physical therapy is projected to grow at 8.87% CAGR through 2031, which makes it the fastest-growing treatment category in the United States brachial plexus injury market. This change reflects a broader clinical shift, because rehabilitation is increasingly treated as a co-primary pathway rather than something that starts only after surgery. German clinical guidance published in 2024 placed high importance on long-term ergotherapy and physiotherapy in interdisciplinary peripheral nerve care, and that position aligns with how leading U.S. programs now structure treatment planning. Medication and rehabilitation services, therefore, continue to support the United States brachial plexus injury industry even when delayed presentation, comorbidity, or payer rules prevent surgery.

By Patient Demographics: Birth Injury Volume Sustains Infant Segment

Infants accounted for 44.42% of the patient demographic segment in 2025, and that makes birth injury a central demand base for the United States brachial plexus injury market. Brachial plexus birth injuries occurred in the range of 1 to 3 per 1,000 births in U.S. literature, and the condition remains strongly associated with shoulder dystocia during delivery. U.S. incidence has also been described as high relative to other industrialized settings, and the relationship between cesarean rates and lower birth injury incidence adds a structural policy dimension to the United States brachial plexus injury market. Because early intervention often determines long-term arm and shoulder function, the infant segment supports steady demand for evaluation, observation, and microsurgical decision-making.

The elderly segment is expected to grow at 7.87% CAGR through 2031, which gives the United States brachial plexus injury market a second major demographic growth layer. Older patients bring a different clinical mix because fall-related injuries, polytrauma, and higher baseline comorbidity can alter both surgical selection and rehabilitation pace. Adult patients still remain the largest single pool for traumatic presentations tied to motor vehicle and occupational events, and they continue to anchor the highest-acuity surgical stream. This three-part demographic structure keeps the United States brachial plexus injury market broad, with infant cases stabilizing demand and adult and elderly cases shaping future growth.

By Diagnostic Method: EMG Anchors Volume as MRI Captures Complex Nerve Mapping

EMG held 36.71% of the diagnostic method segment in 2025, which reflects its role as the routine electrodiagnostic anchor in the United States brachial plexus injury market. It remains central to baseline denervation assessment, injury severity grading, and serial tracking of reinnervation after reconstructive care. That repeat-use profile supports steady utilization because EMG is relevant at diagnosis, during recovery, and in follow-up when clinicians need objective evidence of motor return. Ultrasound adds another useful layer by providing structural visualization and helping guide procedural planning in both anesthetic and surgical settings.

MRI is the fastest-growing diagnostic method, advancing at 8.14% CAGR through 2031, and that pace shows how imaging is moving deeper into decision-making for the United States brachial plexus injury market. Artificial intelligence compressed sensing has already shortened brachial plexus MRI neurography to under 3 minutes while preserving signal quality and interobserver consistency. The 3D SHINKEI sequence has also shown value in separating preganglionic from postganglionic injury, which directly affects surgical strategy and is not something EMG can resolve on its own. As a result, the United States brachial plexus injury market is shifting toward a more layered diagnostic workflow in which EMG retains volume leadership while MRI captures more of the complex mapping role.

By End User: Hospital Workflows Adapt as Ambulatory Centers Absorb Nerve Procedures

Hospitals held 43.12% of the United States brachial plexus injury market share in 2025, and they remain the dominant end-user setting because they control the most complex reconstructions. This leadership reflects their access to trauma teams, intraoperative neuromonitoring, advanced anesthesia support, and post-operative observation capacity that long and technically difficult plexus repairs often require. Specialty clinics and rehabilitation centers still play a large part in the United States brachial plexus injury market because patients need repeated evaluations, therapy sessions, pain management, and long-term monitoring over months or years. CMS reinforced the importance of specialized outpatient nerve repair when it created APC 5433, a new Level 3 Nerve Procedure Code effective January 2026, for nerve allograft repair.

Ambulatory surgical centers are projected to grow at 7.63% CAGR through 2031, making them the fastest-expanding end-user category in the United States brachial plexus injury market. That growth is tied directly to reimbursement changes, since nerve allograft repair reimbursement in ambulatory surgical centers has increased 221% since 2019. Wider outpatient coverage and dedicated peripheral nerve suites are making lower-acuity and selected reconstructive procedures easier to shift away from hospital outpatient departments. Even with that movement, the United States brachial plexus injury market is unlikely to see hospitals lose their central role, because the most severe avulsion and multistage cases still require resources that ambulatory centers cannot fully replicate.

Geography Analysis

The United States brachial plexus injury market benefits from a dense concentration of academic medical centers, higher procedural receptivity, and broader third-party payer support for complex nerve reconstruction than many peer markets. Within the country, expertise is centered in referral hubs such as Boston, New York, Chicago, Houston, and Los Angeles, where Level I trauma centers and dedicated brachial plexus programs receive complex cases from wider catchment areas. This concentration supports high-end surgical volumes, but it also means access is uneven outside major metro corridors. Global surgical practice data also showed that North America favored a later mean intervention age of 10.4 months for neonatal brachial plexus palsy, which extends the period of pre-operative observation and diagnostic testing that supports EMG and MRI demand.

Sun Belt states such as Texas, Florida, and Arizona represent some of the most attractive growth pockets within the United States brachial plexus injury market. Their appeal comes from population growth, expanding healthcare infrastructure, strong outpatient surgery investment, and exposure to road trauma patterns that support procedure demand. These states also carry a growing elderly population, which aligns with the fastest-growing patient demographic in the United States brachial plexus injury market. The same regional mix of demographic growth, trauma burden, and site-of-care expansion should keep the Sun Belt ahead of many slower-growing states over the forecast period.